NCT03405155View on ClinicalTrials.gov

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

Nivolumab

Given IV

Trial Locations (4)

10032

Columbia University, New York

19104

Univeristy of Pennsylvania, Philadelphia

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER